Squandering much of what could have been a good opportunity to better understand the pricing of prescription drugs, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee reverted to political bickering over repeal of the Affordable Care Act (ACA) in the first of a series of three hearings billed as a bipartisan fact-finding into the who, what and why of drug prices.